We are excited to share a major milestone in the advancement of our technology within the thoracic oncology field.
Research presented by a team from the University of Pennsylvania and Integro Theranostics at the recent IASLC 2025 World Conference on Lung Cancer (WCLC) utilized our Absofi Reference Targets to support their critical findings in lung cancer.
The Study: Phase 1b Study of Novel Fluorescence Imaging Agent, LS301, for Lung
Cancer Surgery to Localize Tumors and Assess Margins
The poster, titled “Phase 1b Study of Novel Fluorescence Imaging Agent, LS301, for Lung
Cancer Surgery to Localize Tumors and Assess Margins” focused on leveraging clinical reference targets to ensure the reliable, quantitative data integrity for molecular and imaging guidance in thoracic oncology protocols. This research effort underscores the growing trend toward leveraging advanced molecular and imaging guidance to refine cancer treatment protocols.
By incorporating our clinical reference targets, the research team was able to ensure quantitative sensitivity data for their targeted fluorescence dye.
Why Clinical Reference Targets Matter
In highly sensitive and regulated fields like oncology, the reliability of quantitative data is paramount. Our reference targets provide a standardized, traceable benchmark essential for:
- Validation: Confirming that imaging and sensing devices maintain accuracy across multiple procedures and sites.
- Consistency: Ensuring measurements taken at the University of Pennsylvania are consistent and comparable to data collected globally.
- Auditability: Establishing a clear chain of evidence for data quality—a cornerstone of clinical trials and regulatory submissions.
This use by a leading institution like the University of Pennsylvania at a premier global conference is a powerful validation of the rigor and precision built into our products.
We congratulate the research team on their important work and look forward to supporting future studies that push the boundaries of cancer care.
Source Acknowledgment: The research discussed was presented via poster at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. The poster file, “Integro-WCLC-2025-Poster-Presented-FINAL.pdf,”